Artivion Narrows Outlook as NEXUS Nears U.S. Launch
Hospital surgery buyers and aortic device competitors should watch the January 2027 NEXUS launch timeline.
Updated on Nov. 7, 2026 in Healthcare

Artivion narrowed its 2026 revenue outlook to $484 million to $492 million, down slightly at the top of its prior range. The company plans a January 2027 U.S. launch of its NEXUS aortic-arch stent-graft system, which affects device makers and hospital cardiac and vascular surgery programs.
Why it matters
The narrowed range raised the low end and lowered the high end while keeping the midpoint unchanged, signaling tighter expectations rather than a change in direction. The FDA's April 2026 approval of NEXUS is the step that lets the company move toward a U.S. commercial launch, shifting its focus from regulatory clearance to surgeon adoption and hospital purchasing.
Third-quarter revenue rose 9% to $123.8 million from $113.4 million a year earlier, while adjusted EBITDA fell 8% to $22.5 million. The 2026 adjusted EBITDA outlook includes about $8 million in expenses tied to the Endospan acquisition, and the adjusted 2025 revenue excludes a $2.3 million reserve for an estimated repayment to the Italian government.
The players
Artivion
A medical device company focused on cardiovascular surgery products, including aortic repair devices, selling into hospital surgical programs.
The details
The revised revenue range raises the floor and trims the ceiling, leaving the midpoint at the prior level. The revenue outlook assumes currency will add about 1 percentage point to reported full-year revenue, so part of the reported growth reflects exchange rates rather than underlying sales. Adjusted EBITDA is under pressure in the near term because acquisition-related costs from the Endospan deal, which closed in May 2026, are being absorbed into 2026 results.
Timeline
April 2, 2026: FDA approved the NEXUS system.
May 2026: The Endospan acquisition closed.
Quarter ended Sept. 30, 2026: Third-quarter revenue reported at $123.8 million.
December 2026: Planned first surgeon-training event for NEXUS.
January 2027: Planned U.S. commercial launch of NEXUS.
Market Landscape
The FDA's April 2026 approval of NEXUS moves Artivion from regulatory clearance toward commercial competition in aortic-arch repair. The planned launch sequence, with surgeon training in December 2026 and sales in January 2027, follows the typical path for new cardiovascular devices, where early physician adoption shapes hospital purchasing.
Hospital cardiac and vascular surgery procurement teams should track the NEXUS launch timeline for evaluation and purchasing decisions in 2027. Device-industry operators should watch how the narrowed outlook and acquisition costs affect margins, since adjusted EBITDA is absorbing expenses tied to the Endospan deal.
The takeaway
Hospital and device-industry operators should calendar the December 2026 surgeon-training event and January 2027 launch as the next checkpoints for NEXUS adoption. Track whether adjusted EBITDA margins recover once the roughly $8 million in Endospan-related expenses roll off.
What happens next
Artivion plans its first NEXUS surgeon-training event in December 2026 ahead of the planned January 2027 U.S. commercial launch.
Further reading
For more on how medical device launches and hospital purchasing decisions play out, see our Healthcare coverage.
Source note: This article includes information reported by TokenPost.




